Gilead Sciences has agreed to pay $246.8 million to direct purchasers of its HIV medications. This payment settles claims that Gilead had previously made an agreement with Teva Pharmaceuticals to intentionally delay the release of generic versions of its drugs. The resolution arrived shortly before the issue was due to go to trial.
More detailed coverage of this development can be found at Law360.